Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

NCT01046916 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Millennium Pharmaceuticals, Inc.